NeOnc Technologies Holdings Inc. Common Stock (NTHI)

FairStock Score: 19/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, honest accounting, and a margin of safety. NeOnc does not yet qualify. It is a clinical-stage biopharmaceutical company with five employees, working on NEO100 in Phase IIa and NEO212 in Phase I/II for intracranial malignancies. In fiscal 2025, the year ended 2025-12-31, it reported revenue of $39,990 and a net loss of $62.1 million, or $3.20 per diluted share. In fiscal 2024, the year ended 2024-12-31, revenue was $83,000 and net loss was $11.9 million, or $0.69 per diluted share. Losses widened sharply while revenue was negligible. Recent quarters show continued burn: in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $14.2 million, or $0.58 per diluted share, versus a $5.7 million loss, or $0.30 per share, in fiscal Q2 2025, the quarter ended 2025-06-30. FairStock's trailing free cash flow is -$21.7 million, a -32.2% FCF yield. At the 2026-10-13 close of $2.60, market cap was $67.3 million; FairStock's P/E is -1.22, ROCE -634.99%, Piotroski 4/9, and Altman Z-Score -59.19. There is no meaningful moat I can identify: no approved product, no recurring revenue, and no multi-year record. The stock is far below its 52-week high of $12.00 and near its low of $2.50, but cheapness versus sales is not relevant with only $39,990 of fiscal 2025 revenue. This is an option on clinical success, not a Graham value investment. Without trial data or financing details, I cannot underwrite a margin of safety.

In plain English: NeOnc Technologies is a tiny drug developer working on treatments for brain cancers. It has almost no revenue, loses tens of millions of dollars, and has no approved product. At $2.60 a share, the company is valued at about $67 million, but with no profits the price mainly reflects hopes for future trial results rather than a proven, cheap business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer